Navigation Links
Bioheart, Inc., Board Appoints Howard J. Leonhardt Chief Executive Officer
Date:7/3/2008

SUNRISE, Fla., July 3 /PRNewswire-FirstCall/ -- Bioheart, Inc., (Nasdaq: BHRT) a biotechnology company that is focused on the development of autologous (patient-derived) cell therapies and devices for the treatment of chronic and acute heart damage, today announced that its Board of Directors appointed Howard J. Leonhardt, Bioheart's co-founder, Chairman of the Board and Chief Technology Officer, to serve as Chief Executive Officer effective as of July 1, 2008. This follows the resignation of William M. Pinon as the Company's President and CEO and as a member of the Board of Directors as of the same date. Pinon has agreed to remain with the Company through July 25, 2008 to assist in the executive transition process.

"Bill has been a tremendous asset to Bioheart during his tenure and we are sorry to see him leave in order to pursue other interests," said Leonhardt. "Under his leadership, Bioheart became a publicly traded company and advanced the base of clinical evidence regarding our MyoCell(R) clinical cell therapy, including initiation of our potentially pivotal Phase II/III MARVEL Trial in the US and Europe. I look forward to a greater level of involvement as we continue to pursue regulatory approval and commercialization of this therapy to treat congestive heart failure patients, as well as, drive the development of future generation products. We look to the future with great anticipation."

ABOUT BIOHEART

Bioheart, Inc. (NASDAQ: BHRT) is a biotechnology company focused on the discovery, develo
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Bioheart, Inc., Added to Russell Microcap Index
2. Bioheart, Inc. to Transfer to Nasdaq Capital Market
3. Bioheart, Inc. to Host Annual Meeting of Shareholders on Wednesday, July 30, 2008
4. Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
5. Bioheart, Inc. Announces Financial Results for First Quarter 2008
6. Bioheart, Inc. to Report Full Year 2007 Financial Results on Thursday, March 27, 2008
7. Arizona-Based SenesTech, Inc., Partners With Australia to Stop Starvation Due to Rice Shortages
8. Paul J. Mirabella, President and CEO of Naviscan PET Systems Inc., Joins GenVaults Board of Directors
9. Solei Systems, Inc., Announces That the Company Is Now Publicly Traded
10. Sangui BioTech International, Inc., Reports Sales Increase, Continued Losses
11. Elsevier Acquires Windhover Information Inc., a Healthcare Business Intelligence Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... -- On behalf of biotech client GenScript USA, ... & Spitzer, P.A. (Wilentz) secured a significant jury verdict ... excess of $10 million. The jury determined that Genewiz ... it improperly hired one or more of GenScript,s employees.  ... notwithstanding the verdict, a new trial, and remittitur. ...
(Date:2/26/2015)... , Feb. 26, 2015 Protiviti ( www.protiviti.com ... version of the Governance Portal , designed to ... and compliance (GRC) tasks across multiple business units and ... to help customers better align their controls with the ... Commission ) requirements. In response to client feedback, Protiviti ...
(Date:2/26/2015)... -- The healthcare landscape is rapidly and radically changing. To ... host its 20 th Anniversary Medical Technologies 2015: ... 10, at the Hilton San Diego Resort and Spa in ... event is a platform for global medical devices, diagnostics, life ... how to succeed in an uncertain future. Participants ...
(Date:2/26/2015)... 2015 RURO, Inc., a leading LIMS, ... 6.2 – the latest update to the bestselling commercial-off-the-shelf ... of a quick and easy method to gain better ... version, RURO engineering has enhanced the system’s support for ... amounts of sample records. , "FreezerPro has become ...
Breaking Biology Technology:Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3RURO Releases FreezerPro® version 6.2 2
... Science ... ... -- DuPont was named the 2009 recipient of the Corporate Innovation Award by the ... that has made a substantial difference in the marketplace and global community., , , ...
... experiment by college students that will study how microbes grow ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20081007/38461LOGO ) , ... developed the experiment that will fly as part of the ... p.m. EST on Nov. 16 from NASA,s Kennedy Space Center ...
... 12 Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH ), ... I/II open-label dose-ranging trial with Apoptone® (HE3235) for hormone-resistant ... on November 16 at the American Association for Cancer ... Boston. Apoptone, a novel steroid that is an ...
Cached Biology Technology:DuPont Receives Corporate Innovation Award 2DuPont Receives Corporate Innovation Award 3DuPont Receives Corporate Innovation Award 4Students Send Microbe Experiment on Space Shuttle Atlantis 2Students Send Microbe Experiment on Space Shuttle Atlantis 3Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference 2Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference 3Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference 4Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference 5
(Date:2/11/2015)... , February 11, 2015 ... report "Access Control Market by Product (Cards and Readers, ... Military and Defense, Government, Industrial, Healthcare, Education) and By ... by MarketsandMarkets, the Access Control Market is ... growing at a CAGR of 10.6% between ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America recently ... for carbon nanotube (CNT) macrostructures, including sheets, yarns and ... (UTD). Leveraging the vast industrial resources of ... Japan , Lintec of America is forming the ... TX , focusing on scaling up the manufacturing ...
(Date:2/5/2015)... , Feb. 5, 2015  Marken is starting ... company and has launched a new marketing campaign to ... Organization (CLO).  The new campaign focuses on First ... protocol and shipments. The first headline in ... aligns Marken,s priorities with its client,s priorities. Marken recognizes ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marken Launches New Patient-Centric Campaign 2
... immune system's pro-inflammatory response to bacterial invasion is ... called inducible nitric oxide synthase. In a study ... report that the predominantly anti-inflammatory enzyme, endothelial nitric ... production in response to infection. This discovery may ...
... Until now it has been impossible to accurately measure ... in real time and at the level of a ... Plant Biology and Stanford University are the first to ... molecular sensors to view changes in brain chemical levels. ...
... (MGH) has identified 80 new genes essential to the ... tool for inactivating genes in plants or animals. They ... that participate in the gene-silencing mechanism, which someday may ... in the journal Science and is receiving early online ...
Cached Biology News:Researchers report new pro-inflammatory role for anti-inflammatory enzyme 2Revolutionary nanotechnology illuminates brain cells at work 2Revolutionary nanotechnology illuminates brain cells at work 3Scientists identify genetic pathways essential to RNA interference 2Scientists identify genetic pathways essential to RNA interference 3
... to the maintenance of appropriate levels ... important and diverse as those involved ... stress response, antigen presentation, modulation of ... cell cycle regulation, transcription, and signalling ...
... This protein identification Service includes 1. ... protein spots 3. High-sensitive tryptic in-gel ... of samples for MALDI-MS 5. Acquisition ... via MALDI-MS (Bruker ultraflex TOF/TOF) 6. ...
... The Vibratome Company has joined forces ... introduce the Vibratome 411301 Tissue Chopper. This ... prepare sections of tissue for metabolic experiments ... and irregular specimens available at biopsy or ...
... The ProteinChip Antibody Capture ... development and optimization steps ... antibody-antigen interactions. This kit ... differentiation of multiple antigens ...
Biology Products: